Met Life Investment Management, LLC Ovid Therapeutics Inc. Transaction History

Met Life Investment Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.7 - $3.34 $11,757 - $56,098	-16,796 Closed	0 $0
Q1 2024 May 14, 2024	BUY	$2.72 - $4.04 $45,685 - $67,855	16,796 New	16,796 $51,000
Q3 2023 May 09, 2024	BUY	$3.23 - $3.97 $102,445 - $125,916	31,717 New	31,717 $121,000
Q2 2023 Apr 29, 2024	BUY	$2.53 - $3.89 $80,244 - $123,379	31,717 New	31,717 $104,000
Q2 2023 Aug 10, 2023	BUY	$2.53 - $3.89 $80,244 - $123,379	31,717 New	31,717 $104,000
Q4 2020 Feb 16, 2021	SELL	$2.28 - $6.84 $47,740 - $143,222	-20,939 Closed	0 $0
Q3 2020 Jun 26, 2023	BUY	$5.39 - $8.24 $112,861 - $172,537	20,939 New	20,939 $120,000
Q2 2020 May 24, 2024	BUY	$2.67 - $7.91 $11,061 - $32,771	4,143 Added 24.67%	20,939 $154 Million
Q2 2020 Jun 26, 2023	BUY	$2.67 - $7.91 $55,907 - $165,627	20,939 New	20,939 $154,000
Q2 2020 Mar 22, 2023	BUY	$2.67 - $7.91 $55,907 - $165,627	20,939 New	20,939 $154,000
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $55,907 - $165,627	20,939 New	20,939 $154,000

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $70.4M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.